CML is highly dependent on the existence of BCR-ABL [31], hence, downregulating BCR-ABL oncoprotein by small molecule compounds, via mRNA level or protein level, may be applied as a promising therapies for CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.